Epigenomics AG Licenses Biomarker for Colorectal Cancer Blood Test to ARUP Laboratories
ARUP to commercialize laboratory-developed blood test based on Epigenomics' mSEPT9 biomarker to aid in the early detection of colorectal cancer
14-Aug-2009 -
Epigenomics AG announced that it signed a non-exclusive licensing agreement for its proprietary DNA methylation biomarker Septin 9 (mSEPT9) with Salt Lake City, Utah, U.S. based ARUP Laboratories, Inc. (ARUP). Under the agreement, ARUP has obtained rights to use the mSEPT9 biomarker to develop a ...
blood tests
colorectal cancer
DNA methylation